CDKN2A and hepatocellular carcinoma: Alterations of cell cycle regulators, such as increased CDK4 expression/activity or p16INK4a inactivation, have been frequently reported in HCC, providing the rationale to test CDK4/6 inhibitors for HCC treatment (53).